Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

ICU Telemedicine Solutions.

Fuhrman SA, Lilly CM.

Clin Chest Med. 2015 Sep;36(3):401-7. doi: 10.1016/j.ccm.2015.05.004. Epub 2015 Jun 27. Review.

PMID:
26304277
2.

Intensive care unit-acquired hypernatremia is an independent predictor of increased mortality and length of stay.

Waite MD, Fuhrman SA, Badawi O, Zuckerman IH, Franey CS.

J Crit Care. 2013 Aug;28(4):405-12. doi: 10.1016/j.jcrc.2012.11.013. Epub 2013 Jan 29.

PMID:
23369520
3.

Association between intensive care unit-acquired dysglycemia and in-hospital mortality.

Badawi O, Waite MD, Fuhrman SA, Zuckerman IH.

Crit Care Med. 2012 Dec;40(12):3180-8. doi: 10.1097/CCM.0b013e3182656ae5.

PMID:
22971590
4.

In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Shi ST, Herlihy KJ, Graham JP, Fuhrman SA, Doan C, Parge H, Hickey M, Gao J, Yu X, Chau F, Gonzalez J, Li H, Lewis C, Patick AK, Duggal R.

Antimicrob Agents Chemother. 2008 Feb;52(2):675-83. Epub 2007 Dec 10.

5.

Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.

Hao W, Herlihy KJ, Zhang NJ, Fuhrman SA, Doan C, Patick AK, Duggal R.

Antimicrob Agents Chemother. 2007 Jan;51(1):95-102. Epub 2006 Oct 23.

6.

Analytic bias of thyroid function tests: analysis of a College of American Pathologists fresh frozen serum pool by 3900 clinical laboratories.

Steele BW, Wang E, Klee GG, Thienpont LM, Soldin SJ, Sokoll LJ, Winter WE, Fuhrman SA, Elin RJ.

Arch Pathol Lab Med. 2005 Mar;129(3):310-7.

PMID:
15737023
7.

The crystal structure of the RNA-dependent RNA polymerase from human rhinovirus: a dual function target for common cold antiviral therapy.

Love RA, Maegley KA, Yu X, Ferre RA, Lingardo LK, Diehl W, Parge HE, Dragovich PS, Fuhrman SA.

Structure. 2004 Aug;12(8):1533-44.

8.

An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents.

Ettinger A, Ostroff R, Rhihanek M, Dragovich PS, Zalman LS, Patick AK, Prins TJ, Fuhrman SA, Brown EL, Worland ST, Polisky B.

Antiviral Res. 2004 Mar;61(3):153-9.

PMID:
15168795
9.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW 3rd, Ferre RA.

J Med Chem. 2003 Oct 9;46(21):4572-85.

PMID:
14521419
10.

Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme.

Love RA, Parge HE, Yu X, Hickey MJ, Diehl W, Gao J, Wriggers H, Ekker A, Wang L, Thomson JA, Dragovich PS, Fuhrman SA.

J Virol. 2003 Jul;77(13):7575-81. Erratum in: J Virol. 2003 Sep;77(18):10176.

11.

Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.

Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW 3rd, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS.

J Med Chem. 2002 May 9;45(10):2016-23.

PMID:
11985469
12.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 2002 Apr 11;45(8):1607-23.

PMID:
11931615
13.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):733-8.

PMID:
11858991
14.

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.

Webber SE, Marakovits JT, Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Srinivasan B, Moran T, Ford CE, Brothers MA, Harr JE, Meador JW 3rd, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2683-6.

PMID:
11591501
15.

Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.

Reich SH, Johnson T, Wallace MB, Kephart SE, Fuhrman SA, Worland ST, Matthews DA, Hendrickson TF, Chan F, Meador J 3rd, Ferre RA, Brown EL, DeLisle DM, Patick AK, Binford SL, Ford CE.

J Med Chem. 2000 May 4;43(9):1670-83.

PMID:
10794684
16.

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, Fuhrman SA, Zalman LS, Maldonado FC, Brown EL, Meador JW 3rd, Patick AK, Ford CE, Brothers MA, Binford SL, Matthews DA, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):45-8.

PMID:
10636240
17.

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST.

Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50.

18.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11000-7.

19.

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.

Dragovich PS, Webber SE, Prins TJ, Zhou R, Marakovits JT, Tikhe JG, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Brown EL, Binford SL, Meador JW 3rd, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2189-94.

PMID:
10465543
20.

Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides.

Dragovich PS, Zhou R, Skalitzky DJ, Fuhrman SA, Patick AK, Ford CE, Meador JW 3rd, Worland ST.

Bioorg Med Chem. 1999 Apr;7(4):589-98.

PMID:
10353638
21.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW 3rd, Ferre RA, Harr JE, Kosa MB, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1213-24.

PMID:
10197965
22.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1203-12.

PMID:
10197964
23.

Interaction of a novel GDP exchange inhibitor with the Ras protein.

Ganguly AK, Wang YS, Pramanik BN, Doll RJ, Snow ME, Taveras AG, Remiszewski S, Cesarz D, del Rosario J, Vibulbhan B, Brown JE, Kirschmeier P, Huang EC, Heimark L, Tsarbopoulos A, Girijavallabhan VM, Aust RM, Brown EL, DeLisle DM, Fuhrman SA, Hendrickson TF, Kissinger CR, Love RA, Sisson WA, Webber SE, et al.

Biochemistry. 1998 Nov 10;37(45):15631-7.

PMID:
9843367
24.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2819-34.

PMID:
9667971
25.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2806-18.

PMID:
9667970
26.

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

Webber SE, Okano K, Little TL, Reich SH, Xin Y, Fuhrman SA, Matthews DA, Love RA, Hendrickson TF, Patick AK, Meador JW 3rd, Ferre RA, Brown EL, Ford CE, Binford SL, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2786-805.

PMID:
9667969
27.

Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.

Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL, DeLisle DM, Ford CE, Binford SL.

J Med Chem. 1996 Dec 20;39(26):5072-82.

PMID:
8978838
28.

Delivering clinical laboratory services to intensive care units.

Steffes MW, Gillen JL, Fuhrman SA.

Clin Chem. 1996 Mar;42(3):387-91.

29.

The mobile laboratory in alternative site testing.

Fuhrman SA, Travers EM, Handorf CR.

Arch Pathol Lab Med. 1995 Oct;119(10):939-42.

PMID:
7487395
30.

Mutations that abolish the ability of Ha-Ras to associate with Raf-1.

Shirouzu M, Koide H, Fujita-Yoshigaki J, Oshio H, Toyama Y, Yamasaki K, Fuhrman SA, Villafranca E, Kaziro Y, Yokoyama S.

Oncogene. 1994 Aug;9(8):2153-7.

PMID:
8036000
31.

Toxoplasma gondii: fusion competence of parasitophorous vacuoles in Fc receptor-transfected fibroblasts.

Joiner KA, Fuhrman SA, Miettinen HM, Kasper LH, Mellman I.

Science. 1990 Aug 10;249(4969):641-6.

PMID:
2200126
32.

Complement evasion by protozoa.

Fuhrman SA, Joiner KA.

Exp Parasitol. 1989 May;68(4):474-81. Review. No abstract available.

PMID:
2656282
33.

Toxoplasma gondii: mechanism of resistance to complement-mediated killing.

Fuhrman SA, Joiner KA.

J Immunol. 1989 Feb 1;142(3):940-7.

PMID:
2643665
34.

Appropriate laboratory testing in the screening and work-up of Cushing's syndrome.

Fuhrman SA.

Am J Clin Pathol. 1988 Sep;90(3):345-50. Review.

PMID:
2843035
35.

Marked hyperbilirubinemia in infectious mononucleosis. Analysis of laboratory data in seven patients.

Fuhrman SA, Gill R, Horwitz CA, Henle W, Henle G, Kravitz G, Baldwin J, Tombers J.

Arch Intern Med. 1987 May;147(5):850-3.

PMID:
3034177
36.

Hyponatremia and ion-selective electrodes.

Fuhrman SA, Eckfeldt JH.

Ann Intern Med. 1985 Jun;102(6):872. No abstract available.

PMID:
3994208
37.

Prolonged survival after bilateral thoracotomy for metastatic alveolar soft-part sarcoma.

Berman TM, Fuhrman SA, Johnson FE.

Minn Med. 1984 May;67(5):261-2. No abstract available.

PMID:
6727818
39.

Prognostic significance of morphologic parameters in renal cell carcinoma.

Fuhrman SA, Lasky LC, Limas C.

Am J Surg Pathol. 1982 Oct;6(7):655-63.

PMID:
7180965
40.

Natural cytotoxicity in AKR/J mice during adjuvant induced amyloidogenesis.

Fuhrman SA, Parkinson DR, Waksal SD, McAdam KP.

Cell Immunol. 1982 Jun;70(1):170-9. No abstract available.

PMID:
6180838
41.

Analysis of transcription of the human Alu family ubiquitous repeating element by eukaryotic RNA polymerase III.

Fuhrman SA, Deininger PL, LaPorte P, Friedmann T, Geiduschek EP.

Nucleic Acids Res. 1981 Dec 11;9(23):6439-56.

42.
43.

Transcription and processing of intervening sequences in yeast tRNA genes.

Knapp G, Beckmann JS, Johnson PF, Fuhrman SA, Abelson J.

Cell. 1978 Jun;14(2):221-36.

PMID:
352537
44.

Adrenocorticotropic hormone regulation of adrenal RNA polymerases. Stimulation of nuclear RNA polymerase III.

Fuhrman SA, Gill GN.

Biochemistry. 1976 Dec 14;15(25):5520-7. No abstract available.

PMID:
187219
46.

Hormonal control of adrenal RNA polymerase activities.

Fuhrman SA, Gill GN.

Endocrinology. 1974 Mar;94(3):691-700. No abstract available.

PMID:
4360475

Supplemental Content

Loading ...
Support Center